Pharmacokinetics of conivaptan use in patients with severe hepatic impairment

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment

Thomas Marbury,1 Jerry Fox,2 Byron Kaelin,2 Leo Pavliv2 1Orlando Clinical Research Center, Inc., Orlando, FL, 2Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA Purpose: Conivaptan is an intravenous dual V1A/V2 vasopressin antagonist approved for the trea...

Full description

Bibliographic Details
Main Authors: Marbury T, Fox J, Kaelin B, Pavliv L
Format: Article
Language:English
Published: Dove Medical Press 2017-02-01
Series:Drug Design, Development and Therapy
Subjects:
liver
hyponatremia
AVP antagonist
cirrhosis
Online Access:https://www.dovepress.com/pharmacokinetics-of-conivaptan-use-in-patients-with-severe-hepatic-imp-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/pharmacokinetics-of-conivaptan-use-in-patients-with-severe-hepatic-imp-peer-reviewed-article-DDDT

Similar Items